Press Release June 08, 2020

Pliant Therapeutics Closes $165.6 Million IPO and Full Exercise of Option to Purchase Additional Shares

The Life Sciences practice advised Pliant Therapeutics, Inc. (Nasdaq: PLRX), on its $165.6 million initial public offering of 10,350,000 shares of common stock, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 1,350,000 shares of common stock, at a public offering price of $16.00 per share. 
Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
The Goodwin team was led by Sam Zucker, Deepa Rich, James Xu, Michael Rosenberg, Carly Ward, and Qing Han, and included Anitha Anne, Andrew Whitworth, Julie Tibbets, Elizabeth Mulkey, Roger Cohen, Bryna Shmerling, Crescent Chasteen, Grace Wirth, Tony Guan, Dan Karelitz, Matt Dunay, Rick Kline, Ettore Santucci, Robert Dzialo, James Matarese, and Nathan Needle, with invaluable paralegal assistance from, Tricia Hojo and Ruowen Li.
For more details, read the press release and articles in Law360, FierceBiotech, and Silicon Valley Business Journal.